Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Beclomethasone dipropionate (also called BDP; Clenil; Qvar; Beconase; alanase; Vancenase) is a topical anti-inflammatory corticosteroid approved for use in treatment of asthma and rhinitis. In addition, Beclomethasone dipropionate has been reported to be previously developed as aqueous nasal formulations for the treatment of Allergic rhinitis. Moreover, Beclomethasone dipropionate has shown the availability in dry nasal aerosol formulations as chiorofluoro carbon metered-dose inhaler nasal sprays.
ln Vitro |
In 16HBE cells, beclometasone dipropionate (1-100 nM; 20 min) decreases the amounts of NT, ROS, and iNOS produced by rhIL-17A as well as STAT-1 expression[2].
|
---|---|
ln Vivo |
Beclometasone dipropionate (150 µg/kg; nebulization; male BALB/c mice) reduces the relative eosinophil number and total cell count while relieving asthma[1].
|
Cell Assay |
Western Blot Analysis[2]
Cell Types: 16HBE cells Tested Concentrations: 1, 10 and 100 nM Incubation Duration: 20 min Experimental Results: decreased the levels of iNOS, ROS and NT generated by rhIL-17A. |
Animal Protocol |
Animal/Disease Models: Tenweeks old male balb/c (Bagg ALBino) mouse[2].
Doses: 5 mg/kg (100 μg/ml for 60 min). Route of Administration: Orally at 24 h and 1 h before the LPS aerosol. Experimental Results: Dramatically (P < 0.05) inhibited the decrease of IL-10 level in BAL fluid induced by LPS exposure. Markedly decreased the release of both MMP-2 and MMP-9. Animal/Disease Models: Male balb/c (Bagg ALBino) mouse with asthma[1] Doses: 150 µg/kg Route of Administration: Nebulization Experimental Results: diminished total cell number and relative eosinophil number in BALF . |
References |
[1]. Hrvacić B, et, al. Applicability of an ultrasonic nebulization system for the airways delivery of beclomethasone dipropionate in a murine model of asthma. Pharm Res. 2006 Aug;23(8):1765-75.
[2]. Montalbano AM, et, al. Beclomethasone dipropionate and formoterol reduce oxidative/nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial epithelial cells. Eur J Pharmacol. 2013 Oct 15;718(1-3):418-27. |
Molecular Formula |
C28H37CLO7
|
|
---|---|---|
Molecular Weight |
521.04
|
|
CAS # |
5534-09-8
|
|
Related CAS # |
Betamethasone dipropionate;5593-20-4;Beclometasone dipropionate-d10;Beclometasone;4419-39-0;Beclometasone dipropionate-d6;Beclometasone dipropionate monohydrate;77011-63-3
|
|
SMILES |
C[C@@]12[C@](C[C@H](C)[C@]2(OC(CC)=O)C(COC(CC)=O)=O)([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C1)=O
|
|
InChi Key |
KUVIULQEHSCUHY-XYWKZLDCSA-N
|
|
InChi Code |
InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
|
|
Chemical Name |
(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-[2-(propionyloxy)acetyl]-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9192 mL | 9.5962 mL | 19.1924 mL | |
5 mM | 0.3838 mL | 1.9192 mL | 3.8385 mL | |
10 mM | 0.1919 mL | 0.9596 mL | 1.9192 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.